entertainment -WSS

entertainment

author：focus 2025-09-28 02:47:30 - browse：7731

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

focus

WSS

What Congress can do to address the rural doctor shortage

Intarcia’s device

At ASCO, AstraZeneca reports strong data for breast cancer drug

Thermo Fisher plant for manufacturing gene therapies to expand

At ASCO, AstraZeneca reports strong data for breast cancer drug

Ultragenyx gene therapy for rare liver ailment succeeds in late

focus

entertainment

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Ukraine and a new approach to mental health in war

Dobbs anniversary: the lost opportunity of abortion as health care

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Psychedelics group wrestles with new pharma identity

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

At least 13 dead in Texas as scorching temps continue

EpiPen alternative approval delay highlights citizen petition issue

Tori Bowie and the unacceptable rates of Black maternal death

Change Healthcare can notify patients about the breach, HHS says

entertainment

Woman returns to dialysis after doctors remove transplanted pig kidney

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Changes to biosimilar regulatory framework must prioritize patients

Experts study whether long Covid risk adds up with each reinfection

Letters to First Opinion on caregivers, digital health, and more

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

leisure time

focus

focus

Wikipedia